Data science leader to advance Valo’s leading human causal biology platform for drug discoveryLEXINGTON, Mass.--(BUSINESS ...

(NASDAQ: ALMU), a semiconductor company specializing in high-performance, scalable technologies for mobile, AI, defense and aerospace, robotics, automotive, AR/VR, and quantum, announced today it has ...

Researchers asked people from different countries to rank the morality and ethics of their fellow citizens. The results could ...

DeepCyte, a techbio company building AI toxicology tools for drug development, launched today with $1.5 million in seed funding. The company is introducing two solutions to help biopharma teams detect ...

Genetic profiling of type 2 diabetes subgroups has enabled researchers to predict coronary artery disease risk prior to ...

The Shanghai-based start-up says its chip design is likely to improve energy efficiency by 40 per cent compared with its predecessor Chinese chip start-up Dishan Technology has achieved a breakthrough ...

Today, JCET Group (SSE: 600584), a leading global provider of integrated circuit (IC) back-end manufacturing and technology services, released its 2025 Annual Report. JCET reported record full-year ...

Against the backdrop of growing demand for global ubiquitous connectivity in the 6G era, low-Earth-orbit (LEO) satellite mega-constellations have ...

Acute myeloid leukemia (AML) has a poor prognosis, especially in elderly and relapsed/refractory patients, with 5‑year survival below 30% ...

OpenAI entering cybersecurity was always a question of timing, not possibility. The surprise is not that it wants in. The surprise is how late it waited compared with the rest of the security market.

New psychoactive substances (NPS) are a class of artificially designed and synthesized chemical substances designed to mimic the pharmacological effects of traditional drugs. They are characterized by ...

EED compliance does not require a hardware overhaul. Retrofitting legacy metres with OMS-compliant data concentrators ...